Long intergenic noncoding RNA MIAT regulates human Th17 cell differentiation and is highly expressed in T cells of inflamed synovia in joints of Rheumatoid Arthritis patients
Long intergenic noncoding RNAs (lincRNA) are emerging as novel regulators of biological processes, including cell differentiation and development. While Th17 cells are required for clearing fungal and bacterial infections, dysregulation of Th17 response can result in autoimmunity such as rheumatoid arthritis.
Researchers from Turku Bioscience identified Myocardial Infarction Associated Transcript (MIAT) lincRNA as a novel regulator of human Th17 cells.
First demonstrating that MIAT is significantly upregulated during early human Th17 cell differentiation they then showed that it is regulated by STAT3, a key transcription factor driving Th17 differentiation.
- We found that MIAT is essential for Th17 differentiation; its silencing led to impaired Th17 specification and it positively regulated the expression of several Th17 signature genes, says Professor Riitta Lahesmaa, Director of Turku Bioscience and a group leader in the InFLAMES research flagship initiative.
MIAT resides in the nucleus and appears to regulate the chromatin accessibility of key Th17 loci including IL17A locus.
- Besides discovering MIAT to be functionally essential for Th17 differentiation we found MIAT to be upregulated in T cells of synovial biopsies from patients with rheumatoid arthritis, suggesting its role in the pathogenesis of this autoimmune disease and possibly other autoimmune disorders, says Professor Riitta Lahesmaa.
The study was published in the Frontiers of Immunology. The study was funded by the Academy of Finland, The Sigrid Jusélius Foundation, the Jane & Aatos Erkko Foundation and InFLAMES Flagship.
Khan MM, Khan MH, Kalim UU, Khan S, Junttila S, Paulin N, Kong L, Rasool O, Elo LL, Lahesmaa R. Long Intergenic Noncoding RNA MIAT as a Regulator of Human Th17 Cell Differentiation. Front Immunol. 2022 Jun 15;13:856762. doi: 10.3389/fimmu.2022.856762. eCollection 2022.
More information: Riitta Lahesmaa, riitta.lahesmaa@utu.fi, tel. +358 40 718 4813
Recent Posts
- PFAS levels in mothers’ blood associated with children’s brain structure and function Researchers from the University of Turku and Turku University Hospital, Finland, and Örebro University, Sweden, Read moreOctober 13, 2025
- Professor Laura Elo receives award for outstanding research from the Jenny and Antti Wihuri Foundation The Jenny and Antti Wihuri Foundation awarded Professor of Computational Medicine Laura Elo a €50,000 Read moreOctober 10, 2025
- Recruit your next student at the MSc Thesis Project Expo 2025. Registration is now open! Do you supervise MSc theses in the biosciences? Join the MSc Thesis Project Expo on Read moreOctober 10, 2025
- University of Turku celebrates Professor Shimon Sakaguchi’s Nobel prize Professor Shimon Sakaguchi, winner of the 2025 Nobel Prize in Medicine, is a visiting professor Read moreOctober 7, 2025
- Heidi Isokääntä Successfully Defends Dissertation on Gut Microbiome Development Heidi Isokääntä Successfully Defends Dissertation on Gut Microbiome Deveopment Turku, 26 September 2025 – Bioanalyst Read moreSeptember 29, 2025
- University of Jyväskylä to Award Honorary Doctorate to Johanna Ivaska The University of Jyväskylä will award 11 new honorary doctorates in May 2026. One of Read moreSeptember 26, 2025